Science Exchange

Name: Science Exchange
Brand: Science Exchange
Rating: 4.8 (2 reviews)

Science Exchange’s supplier orchestration platform harmonizes purchasing, supplier management, and payment processing.

Est 2011|Valuation $61M|Raised $83.4M

LinkedIn 11K|Website|Web traffic 10K|FTEs 117|HQ San Francisco, California, US

MarketsSource-to-Contract Supplier Relationship Management (SRM) and Vendor Management (VRM)

Published Sep 17, 2026

01Common complaints

- If independently validated third-party review volume is a prerequisite for procurement decisions: public review coverage is limited and may not provide sufficient evidence for all buyers. - If success depends on immediate access to highly specialized or niche suppliers that are unlikely to be on the marketplace and whose onboarding would introduce delays. - If the organization requires broad, company-wide source-to-pay coverage as a primary requirement and prefers a single vendor procurement platform for all categories; large enterprise procurement suites may be more appropriate in those cases. - If publicly available and current security and compliance documentation (for example, ISO certifications, the current SOC 2 Type II report, and data residency guarantees) is required without engaging in an NDA or vendor questionnaire; these materials were not clearly available in public sources reviewed.

Deal disqualifiers (poor fit)

Organizations that require access to niche suppliers not present in the vendor’s network and are unwilling or unable to onboard those suppliers through the platform.
Organizations that mandate a single enterprise procurement suite and cannot accommodate an overlay tool without deep integration.

Limitations evidenced in reviews

Marketplace coverage is not comprehensive for all supplier niches, based on reviewer comments.
Some suppliers have demonstrated variability in responsiveness to requests placed through the platform.

Limitations evidenced in public information availability

Pricing is not published, which complicates self-serve evaluation for smaller buyers.
Security and compliance certifications and details (e.g., up-to-date SOC 2 Type II reports, ISO certificates, data residency options) were not clearly documented in the public materials reviewed.

Roadmap / future features

No explicit public roadmap with dates or feature release plans was found in the materials accessed for this research.

02Why they buy

Note: unique selling point descriptions distinguish vendor positioning from evidence-based findings. Vendor-claimed unique selling points: - A marketplace and supplier orchestration model oriented to life-sciences outsourcing and contracting under a consolidated supplier agreement. - An orchestration layer designed to coordinate workflow with existing P2P and ERP systems (vendor description). - A supplier network presented by the vendor as containing several thousand suppliers. Evidence supported by available third-party reviews (limited sample): - Reviewers indicated the platform is useful for discovering CROs and broadcasting project scopes to multiple suppliers for comparison. Where competitors may have advantages: - Some marketplace competitors report larger supplier directories or additional sourcing services, while broader procurement suites provide more extensive enterprise procurement modules at the expense of added complexity.

Evidence supported by available third-party reviews (limited sample):

Key Differentiator

03Field reports

Review platform coverage reality check

Public review coverage is limited. One major business review platform shows a very small number of reviews and notes there are insufficient reviews to provide broad buying guidance. Other enterprise review platforms were either inaccessible or did not return a dedicated product page in the searches performed.

Summarized reviewer feedback (paraphrased for neutrality)

Positive themes reported by reviewers and vendor-published testimonials: - Reviewers wrote that the platform facilitated discovery of contract research organizations (CROs) and vendor specialists, and helped broadcast requests to multiple potential suppliers. - Vendor-published testimonial language describes the platform as contributing to shorter R&D timelines; this is presented as the vendor’s customer narrative and is not independently verified in this research. Critical feedback and limitations reported by reviewers: - Some reviewers stated that marketplace coverage is incomplete for certain niche suppliers, meaning required vendors may not always be available via the marketplace. - There were reports of variability in supplier responsiveness; reviewers noted instances where supplier follow-up was required to obtain a timely response. Why reviewers indicated they used the platform (in available feedback): - Faster discovery and sourcing of CROs and vendors, including the ability to send the same scope to multiple suppliers for comparative responses. - Access to services and specialized capabilities that buyers may otherwise need to acquire via capital equipment investments or internal capability development. Why some customers might leave (signals from available sources): - If critical suppliers are absent from the network and onboarding is slow or administratively difficult. - If supplier responsiveness does not meet buyer expectations and the buyer requires more proactive supplier management. Note on evidence strength: the public review sample is limited, so reviewer themes should be treated as directional rather than statistically representative.

Case study: Global biopharma HEOR operations (vendor-published)

Context: A large pharmaceutical company’s HEOR team implemented the platform to address procurement bottlenecks, fragmented vendor management, and administrative burden. The implementation involved unifying intake, standardizing scoping and budget management, automating contracting workflows, and gaining milestone and payment visibility. Reported vendor-published results: - Substantial reduction in supplier onboarding time (presented as a percentage reduction in the case study). - A modeled annual savings estimate presented in the case study, with categories including reduced legal, compliance, and administrative time as well as benefits from earlier evidence submission. - The implementation narrative includes configuration and integration activities, cross-functional onboarding sessions, and periodic business reviews. Critical evaluation and methodology gaps: - The case study is vendor-produced and does not provide an independently audited methodology. - Some savings items include modeled or estimated business-value components (for example, value attributed to earlier market access) rather than fully documented cash savings; the assumptions underlying these models were not disclosed in the excerpted materials. - The buyer is anonymized in the case study, which limits the ability to verify outcomes independently.

04Best fit

Company sizes

Mid-market to enterprise life-sciences organizations are the most plausible fit for full orchestration rollouts.
Smaller biotechnology companies may derive value from marketplace sourcing functions, but procurement rationale and TCO should be evaluated given implementation and integration costs.

Industries / verticals

Pharmaceutical companies, biotechnology firms, and life-sciences R&D functions such as HEOR and real-world evidence groups.

Roles and personas

R&D personnel seeking outsourced capabilities.
Procurement and sourcing leads managing outsourced R&D categories.
Legal and compliance teams requiring standardized contracting and risk screening.
Finance and accounts-payable stakeholders focused on invoice/PO/change-order handling and consolidated reporting.

Qualification criteria (good fit)

Organizations with a high volume of outsourced scientific work across multiple categories.
Functions experiencing friction from decentralized contracting, onboarding, and compliance processes.
Organizations willing to standardize workflows and invest in cross-functional adoption and governance.

05The pitch

What the product does (core value proposition)

Science Exchange is a supplier orchestration platform and an R&D marketplace for life sciences organizations. The product is described by the vendor as standardizing and automating the end-to-end workflow of outsourced scientific work, including intake, supplier selection, contracting/compliance workflows, and payment processing. The vendor also offers access to a supplier network under a master agreement model. Vendor materials state potential reductions in supplier onboarding and contracting time through a single contract and consolidated administrative entity. Key functional themes from vendor materials: - A supplier orchestration layer intended to integrate with accounts payable, procurement-to-pay, and enterprise resource planning systems to coordinate workflows, approvals, and compliance steps. - Marketplace access to a supplier network and the ability to onboard existing suppliers into a consolidated marketplace experience. - Payments automation for purchase orders, change orders, and invoices, plus reporting and dashboard features for spend visibility.

Target market and market positioning

The primary target market is pharmaceutical and biotechnology companies and adjacent life sciences organizations that rely on outsourced R&D and require both timely execution and documented compliance across supplier management processes. Targeting emphasizes operationalizing outsourcing workflows across legal, procurement, finance, and quality/compliance groups.

Get a comprehensive analysis of Science Exchange including market position, competitive landscape, adoption trends, and peer benchmarks.

Download full report →

Published Sep 17, 2026

01Common complaints

If independently validated third-party review volume is a prerequisite for procurement decisions: public review coverage is limited and may not provide sufficient evidence for all buyers.
If success depends on immediate access to highly specialized or niche suppliers that are unlikely to be on the marketplace and whose onboarding would introduce delays.
If the organization requires broad, company-wide source-to-pay coverage as a primary requirement and prefers a single vendor procurement platform for all categories; large enterprise procurement suites may be more appropriate in those cases.
If publicly available and current security and compliance documentation (for example, ISO certifications, the current SOC 2 Type II report, and data residency guarantees) is required without engaging in an NDA or vendor questionnaire; these materials were not clearly available in public sources reviewed.

Deal disqualifiers (poor fit)

Organizations that require access to niche suppliers not present in the vendor’s network and are unwilling or unable to onboard those suppliers through the platform.
Organizations that mandate a single enterprise procurement suite and cannot accommodate an overlay tool without deep integration.

Limitations evidenced in reviews

Marketplace coverage is not comprehensive for all supplier niches, based on reviewer comments.
Some suppliers have demonstrated variability in responsiveness to requests placed through the platform.

Limitations evidenced in public information availability

Pricing is not published, which complicates self-serve evaluation for smaller buyers.
Security and compliance certifications and details (e.g., up-to-date SOC 2 Type II reports, ISO certificates, data residency options) were not clearly documented in the public materials reviewed.

Roadmap / future features

No explicit public roadmap with dates or feature release plans was found in the materials accessed for this research.

02Why they buy

Note: unique selling point descriptions distinguish vendor positioning from evidence-based findings.

Vendor-claimed unique selling points:

A marketplace and supplier orchestration model oriented to life-sciences outsourcing and contracting under a consolidated supplier agreement.
An orchestration layer designed to coordinate workflow with existing P2P and ERP systems (vendor description).
A supplier network presented by the vendor as containing several thousand suppliers.

Evidence supported by available third-party reviews (limited sample):

Reviewers indicated the platform is useful for discovering CROs and broadcasting project scopes to multiple suppliers for comparison.

Where competitors may have advantages:

Some marketplace competitors report larger supplier directories or additional sourcing services, while broader procurement suites provide more extensive enterprise procurement modules at the expense of added complexity.

Evidence supported by available third-party reviews (limited sample):

Key Differentiator

03Field reports

Review platform coverage reality check

Public review coverage is limited. One major business review platform shows a very small number of reviews and notes there are insufficient reviews to provide broad buying guidance. Other enterprise review platforms were either inaccessible or did not return a dedicated product page in the searches performed.

Summarized reviewer feedback (paraphrased for neutrality)

Positive themes reported by reviewers and vendor-published testimonials:

Reviewers wrote that the platform facilitated discovery of contract research organizations (CROs) and vendor specialists, and helped broadcast requests to multiple potential suppliers.
Vendor-published testimonial language describes the platform as contributing to shorter R&D timelines; this is presented as the vendor’s customer narrative and is not independently verified in this research.

Critical feedback and limitations reported by reviewers:

Some reviewers stated that marketplace coverage is incomplete for certain niche suppliers, meaning required vendors may not always be available via the marketplace.
There were reports of variability in supplier responsiveness; reviewers noted instances where supplier follow-up was required to obtain a timely response.

Why reviewers indicated they used the platform (in available feedback):

Faster discovery and sourcing of CROs and vendors, including the ability to send the same scope to multiple suppliers for comparative responses.
Access to services and specialized capabilities that buyers may otherwise need to acquire via capital equipment investments or internal capability development.

Why some customers might leave (signals from available sources):

If critical suppliers are absent from the network and onboarding is slow or administratively difficult.
If supplier responsiveness does not meet buyer expectations and the buyer requires more proactive supplier management.

Note on evidence strength: the public review sample is limited, so reviewer themes should be treated as directional rather than statistically representative.

Case study: Global biopharma HEOR operations (vendor-published)

Reported vendor-published results:

Substantial reduction in supplier onboarding time (presented as a percentage reduction in the case study).
A modeled annual savings estimate presented in the case study, with categories including reduced legal, compliance, and administrative time as well as benefits from earlier evidence submission.
The implementation narrative includes configuration and integration activities, cross-functional onboarding sessions, and periodic business reviews.

Critical evaluation and methodology gaps:

The case study is vendor-produced and does not provide an independently audited methodology.
Some savings items include modeled or estimated business-value components (for example, value attributed to earlier market access) rather than fully documented cash savings; the assumptions underlying these models were not disclosed in the excerpted materials.
The buyer is anonymized in the case study, which limits the ability to verify outcomes independently.

04Best fit

Company sizes

Mid-market to enterprise life-sciences organizations are the most plausible fit for full orchestration rollouts.
Smaller biotechnology companies may derive value from marketplace sourcing functions, but procurement rationale and TCO should be evaluated given implementation and integration costs.

Industries / verticals

Pharmaceutical companies, biotechnology firms, and life-sciences R&D functions such as HEOR and real-world evidence groups.

Roles and personas

R&D personnel seeking outsourced capabilities.
Procurement and sourcing leads managing outsourced R&D categories.
Legal and compliance teams requiring standardized contracting and risk screening.
Finance and accounts-payable stakeholders focused on invoice/PO/change-order handling and consolidated reporting.

Qualification criteria (good fit)

Organizations with a high volume of outsourced scientific work across multiple categories.
Functions experiencing friction from decentralized contracting, onboarding, and compliance processes.
Organizations willing to standardize workflows and invest in cross-functional adoption and governance.

05The pitch

What the product does (core value proposition)

Key functional themes from vendor materials:

A supplier orchestration layer intended to integrate with accounts payable, procurement-to-pay, and enterprise resource planning systems to coordinate workflows, approvals, and compliance steps.
Marketplace access to a supplier network and the ability to onboard existing suppliers into a consolidated marketplace experience.
Payments automation for purchase orders, change orders, and invoices, plus reporting and dashboard features for spend visibility.

Target market and market positioning

Get a comprehensive analysis of Science Exchange including market position, competitive landscape, adoption trends, and peer benchmarks.

Download full report →